Mirikizumab pharmacokinetics and exposure-response relationships in patients with moderately to severely active ulcerative colitis: results from randomised phase 2 and phase 3 induction and maintenance trials

被引：0
|
作者：
Friedrich, S. [1 ]
Chua, L. [1 ]
Zhang, X. C. [1 ]
机构：
[1] Eli Lilly & Co, Immunol, Indianapolis, IN USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P519
引用
收藏
页码：646 / 646
页数：1
相关论文
共 50 条
  • [1] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE RELATIONSHIPS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM RANDOMISED PHASE 2 AND PHASE 3 INDUCTION AND MAINTENANCE TRIALS
    Friedrich, Stuart
    Chua, Laiyi
    Zhang, Xin
    GASTROENTEROLOGY, 2023, 164 (06) : S1217 - S1218
  • [2] Pharmacokinetics and Exposure-Response Relationship of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase2/3 Induction and Maintenance Studies
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Marano, Colleen W.
    Strauss, Richard
    Zhang, Hongyan
    Johanns, Jewel
    Ford, Joyce A.
    Zhou, Honghui
    Davis, Hugh M.
    Colombel, Jean-Frederic
    Reinisch, Walter
    Feagan, Brian G.
    Rutgeerts, Paul J.
    Sandborn, William
    GASTROENTEROLOGY, 2013, 144 (05) : S228 - S229
  • [3] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
    Otani, Yuki
    Chua, Laiyi
    Komocsar, Wendy
    Larkin, Amy E.
    Zhang, Xin
    GASTROENTEROLOGY, 2024, 166 (05) : S822 - S823
  • [4] Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Marano, Colleen W.
    Strauss, Richard
    Zhang, Hongyan
    Johanns, Jewel
    Zhou, Honghui
    Davis, Hugh M.
    Reinisch, Walter
    Feagan, Brian G.
    Rutgeerts, Paul
    Sandbom, William J.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 (01): : 35 - 46
  • [5] Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies
    Friedrich, Stuart
    Chua, Laiyi
    Adams, David H.
    Crandall, Wallace
    Zhang, Xin Cindy
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (02) : 435 - 447
  • [6] Mirikizumab Pharmacokinetics and Exposure-Response Relationships in Patients With Moderately to Severely Active Crohn's Disease in Phase 2 and 3 Studies
    Chua, Laiyi
    Otani, Yuki
    Friedrich, Stuart
    Durand, Frederick
    Zhang, Xin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1056 - S1056
  • [7] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023, : 1479 - 1491
  • [8] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
    Sandborn, W. J.
    Ferrante, M.
    Bhandari, B. R.
    Berliba, E.
    Hibi, T.
    D'Haens, G. Geert R.
    Tuttle, J.
    Krueger, K.
    Friedrich, S.
    Durante, M.
    Arora, V.
    Feagan, B.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54
  • [9] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023,
  • [10] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Laiyi Chua
    Stuart Friedrich
    Xin Cindy Zhang
    Clinical Pharmacokinetics, 2023, 62 (10) : 1479 - 1491
12345